Differential drug resistance acquisition to doxorubicin and paclitaxel in breast cancer cells.
about
MiR-122 Reverses the Doxorubicin-Resistance in Hepatocellular Carcinoma Cells through Regulating the Tumor MetabolismGlucose-dependent regulation of pregnane X receptor is modulated by AMP-activated protein kinase.3D-QSAR AND CONTOUR MAP ANALYSIS OF TARIQUIDAR ANALOGUES AS MULTIDRUG RESISTANCE PROTEIN-1 (MRP1) INHIBITORS.Pregnane X Receptor and Cancer: Context-Specificity is Key.Guiding TRAIL to cancer cells through Kv10.1 potassium channel overcomes resistance to doxorubicin.Overexpression of microRNA-24 increases the sensitivity to paclitaxel in drug-resistant breast carcinoma cell lines via targeting ABCB9.Second-generation proteasome inhibitor carfilzomib enhances doxorubicin-induced cytotoxicity and apoptosis in breast cancer cells.Nuclear receptors and drug metabolism for the personalization of cancer therapy.Pregnane X receptor, constitutive androstane receptor and hepatocyte nuclear factors as emerging players in cancer precision medicine.Opioids and the blood-brain barrier: a dynamic interaction with consequences on drug disposition in brain.Triphenyl Phosphine-Functionalized Chitosan Nanoparticles Enhanced Antitumor Efficiency Through Targeted Delivery of Doxorubicin to Mitochondria.Possible Role of microRNA-122 in Modulating Multidrug Resistance of Hepatocellular Carcinoma.Compound A attenuates toll-like receptor 4-mediated paclitaxel resistance in breast cancer and melanoma through suppression of IL-8.The role of miR-125b-mitochondria-caspase-3 pathway in doxorubicin resistance and therapy in human breast cancer.Cancer stem cells as key drivers of tumour progression.
P2860
Q28551765-A264F111-A58E-48D2-8B50-F03ECA542676Q33594309-3CC6C3B2-2BA6-47F6-83EE-210789D9DBA8Q36604036-1A67C83C-1368-4F62-B400-6D7399F3C697Q37243869-12FA7C73-4AF9-4401-A097-583FA0019ED1Q37302038-02516DB4-FAAC-424A-9043-3D3F6BC3A865Q37407242-5430CCC9-9389-4EBE-9CF5-E7FD1D34E41CQ37687457-28FADF11-318F-47E1-B8C7-BAB124365D6AQ38704025-3F592EBB-D239-403B-A89A-01B07B65F977Q38937177-2F63C9FD-6D66-45C8-A4F2-61A968772CB3Q39285381-236F6713-A39C-4038-8D35-3993D628FEB1Q42255827-BB6AF4B1-F5DF-4B8E-A0E6-CD24C357F759Q49679382-586DAF4D-F46A-4B99-ABA9-0FE3E7144453Q52730051-E070538F-B4F7-43E1-8305-3BDC1F22FE28Q53220492-DCE531F8-0C09-4ACD-A987-18833FF78599Q55122201-A319A5F2-3DA3-4674-8A5B-911CE8BC6672
P2860
Differential drug resistance acquisition to doxorubicin and paclitaxel in breast cancer cells.
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Differential drug resistance a ...... itaxel in breast cancer cells.
@ast
Differential drug resistance a ...... itaxel in breast cancer cells.
@en
Differential drug resistance a ...... itaxel in breast cancer cells.
@nl
type
label
Differential drug resistance a ...... itaxel in breast cancer cells.
@ast
Differential drug resistance a ...... itaxel in breast cancer cells.
@en
Differential drug resistance a ...... itaxel in breast cancer cells.
@nl
prefLabel
Differential drug resistance a ...... itaxel in breast cancer cells.
@ast
Differential drug resistance a ...... itaxel in breast cancer cells.
@en
Differential drug resistance a ...... itaxel in breast cancer cells.
@nl
P2093
P2860
P1476
Differential drug resistance a ...... itaxel in breast cancer cells.
@en
P2093
Fengliang Wang
Ting Zhong
Yuan Sheng
P2860
P2888
P356
10.1186/S12935-014-0142-4
P577
2014-12-21T00:00:00Z
P5875
P6179
1033474287